PR Newswire BiotechOriginal article
SpliSense Initiates Phase 2b Trial of SPL84 in Cystic Fibrosis
Phase 2SPL84Positive
AI Analysis
Summary
SpliSense initiated a Phase 2b randomized, double-blind, placebo-controlled trial evaluating once-weekly inhaled SPL84 in cystic fibrosis patients receiving CFTR modulator therapy, with topline results expected in H2 2027.
Clinical Trial Data
Phase
2b
Importance:5/10
Sentiment:
0.50
Phase 2bCystic FibrosisInhaledCFTR modulatorTrial initiation
Related Companies
Read the original article
Published by PR Newswire Biotech on September 16, 2026 11:00 AM